Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who
have advanced or metastatic cancer. Monoclonal antibodies such as trastuzumab can locate
tumor cells and either kill them or deliver tumor-killing substances to them without harming
normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining trastuzumab with R115777 may kill more tumor cells.